Genovis launches new product: NIMT®FabRICATOR Kit

Genovis launches new product: NIMT®FabRICATOR Kit

At the Antibody Engineering Asia conference in Singapore tomorrow, Genovis will
introduce the NIMT®FabRICATOR Kit—the most effective tool for antibody
fragmenting on the market. The product, which will be launched in a few days, is
a combination of a unique enzyme and nanostructures developed entirely by
Genovis. Genovis will also present the AbDUCTATOR™ and LIBERATOR™ products,
which are two new antibody engineering products that will be launched later this
spring.

This launch means a new method will be available that is better and faster than
any other method currently on the market. The NIMT®FabRICATOR Kit cleaves and
purifies antibody fragment in less than 30 minutes and is more efficient than
competing methods. 

“It's exciting to get to introduce a combination of nanostructures and a unique
enzyme that have such obvious advantages for the customer,” says Sarah
Fredriksson, Genovis' CEO. “This product idea was one of the reasons for the
intellectual property rights acquisition we implemented in May 2007, and it has
led to a creative, fast addition to the company's product portfolio.”

Genovis will focus this new product primarily on the pharmaceutical industry
where intense research based on antibodies is being done. Genovis develops and
markets a series of products that can be likened to a toolbox that facilitates
production, analysis, and modification of antibodies.


Find out more, contact:
Sarah Fredriksson, CEO, Genovis AB
Tel: +46 46 10 12 30
sarah.fredriksson@genovis.com



Genovis is a biotechnology company with distinguished core competency in the
fields of nanotechnology and nanoparticles. The company's patented NIMT®
technology (NanoInducedMagneticTransfer) has been developed in order to enable
the life science industry to conduct effective preclinical research. Genovis
shares are listed on the First North, part of OMX Nordic Exchange. Mangold
Fondkommission AB is a Certified Advisor and guarantor of liquidity to the
company.